|
|
Volumn 26, Issue 11, 2008, Pages 1903-1904
|
|
No evidence for taxane/platinum pharmacogenetic markers: Just lack of power?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
PACLITAXEL;
ANTINEOPLASTIC AGENT;
BRIDGED COMPOUND;
CARBOPLATIN;
CISPLATIN;
TAXANE;
TAXOID;
BLOOD TOXICITY;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
DRUG EFFECT;
GASTROINTESTINAL TOXICITY;
GENE FREQUENCY;
GENETIC POLYMORPHISM;
GENOTYPE;
HUMAN;
LETTER;
NEOPLASM;
NEUROTOXICITY;
OUTCOME ASSESSMENT;
PHARMACOGENETICS;
PRIORITY JOURNAL;
FEMALE;
GENETIC MARKER;
GENETICS;
METHODOLOGY;
NOTE;
OVARY TUMOR;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BRIDGED COMPOUNDS;
CARBOPLATIN;
CISPLATIN;
CLINICAL TRIALS AS TOPIC;
FEMALE;
GENETIC MARKERS;
GENOTYPE;
HUMANS;
OVARIAN NEOPLASMS;
POLYMORPHISM, GENETIC;
RESEARCH DESIGN;
TAXOIDS;
TREATMENT OUTCOME;
|
|
EID: 42949161671
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2007.15.7776 Document Type: Letter |
|
Times cited : (4)
|
|
References (3)
|
